Interpace Biosciences, Inc. (IDXG)

Market Cap	4.31M
Revenue (ttm)	35.70M
Net Income (ttm)	-6.20M
Shares Out	4.27M
EPS (ttm)	-1.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,606
Open	2.57
Previous Close	2.60
Day's Range	2.44 - 2.57
52-Week Range	0.51 - 3.60
Beta	0.78
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 10, 2021

About IDXG

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: May 20, 1998
• Employees: 94
• Stock Exchange: OTCMKTS
• Ticker Symbol: IDXG

Financial Performance

In 2022, IDXG's revenue was $31.84 million, a decrease of -22.94% compared to the previous year's $41.31 million. Losses were -$5.87 million, -60.23% less than in 2021.